Inspire Drops Allergy Drug Development after Phase III Trial Failure
Inspire Pharmaceuticals (Nasdaq: ISPH) is dropping development of an allergy drug to which it acquired rights in 2006.
Before the markets opened Wednesday, Inspire said the drug failed to meet the primary endpoint of the trial. The drug, a nasal spray, was intended as a treatment for seasonal allergic rhinitis.
Inspire licensed the drug from Boehringer Ingelheim International GmbH, which is based in Germany. Terms of the deal were not disclosed.
Inspire paid Boehringer Ingelheim an upfront license fee and agreed to fund development efforts and to pay royalties if the drug had been approved.
“Our analysis of the overall data in this program and the current competitive environment in allergic rhinitis indicate that epinastine nasal spray does not show potential to meet our desired product profile in the United States,” Christy Shaffer, Inspire’s chief executive officer, said in a statement.
“We do not plan to allocate any future resources to this program and will focus on our commercial products and progressing our high-priority development programs,” he added.
Copyright 2012 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Featured
Hot Off The Wire
- Red Hat's new Fedora lead; Cree LED breakthrough; Google, Cisco top 'green' list; Oracle rejects SAP settlement; Yahoo board shakeup
- Will Cisco report progress in its turnaround efforts?
- Cisco server fire threat; Lenovo Android upgrade; cloud startup vs. Cisco; Epic's Blesinski to host awards; Google 'Solve for X'
E-mail Preferences
